How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism
The exact incidence of cancer-associated venous thromboembolism (CA-VTE) in patients with oral and facial cancer (OFC) is not exactly known, and this risk is empirically considered to be low. However, this suggestion may result in disease underdiagnosis, prolong the initiation of adequate therapy, a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/16/7/1011 |
| _version_ | 1797587862020947968 |
|---|---|
| author | Mária Janíčková Tomáš Bolek Lucia Stančiaková Norbert Nagy Marián Mokáň Matej Samoš |
| author_facet | Mária Janíčková Tomáš Bolek Lucia Stančiaková Norbert Nagy Marián Mokáň Matej Samoš |
| author_sort | Mária Janíčková |
| collection | DOAJ |
| description | The exact incidence of cancer-associated venous thromboembolism (CA-VTE) in patients with oral and facial cancer (OFC) is not exactly known, and this risk is empirically considered to be low. However, this suggestion may result in disease underdiagnosis, prolong the initiation of adequate therapy, and consecutively increase CA-VTE-related morbidity and mortality. In addition, there might be specific clinical problems in the treatment of CA-VTE in patients with oral and facial cancer, such as swallowing difficulties, that might limit the possibilities of oral anticoagulation. Finally, there are limited data regarding the optimal treatment of CA-VTE in patients with oral and facial cancer, and this includes data on novel therapeutic strategies, including the use of direct oral anticoagulants. This article reviews current data on the optimal treatment strategy for CA-VTE in patients with OFC. |
| first_indexed | 2024-03-11T00:44:48Z |
| format | Article |
| id | doaj.art-5d5ac398e8a44086b967aea82ecc4367 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-11T00:44:48Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-5d5ac398e8a44086b967aea82ecc43672023-11-18T20:53:07ZengMDPI AGPharmaceuticals1424-82472023-07-01167101110.3390/ph16071011How to Treat Today? Oral and Facial Cancer-Associated Venous ThromboembolismMária Janíčková0Tomáš Bolek1Lucia Stančiaková2Norbert Nagy3Marián Mokáň4Matej Samoš5Department of Stomatology and Maxillofacial Surgery, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaNational Centre of Hemostasis and Thrombosis, Department of Hematology and Blood, Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaThe exact incidence of cancer-associated venous thromboembolism (CA-VTE) in patients with oral and facial cancer (OFC) is not exactly known, and this risk is empirically considered to be low. However, this suggestion may result in disease underdiagnosis, prolong the initiation of adequate therapy, and consecutively increase CA-VTE-related morbidity and mortality. In addition, there might be specific clinical problems in the treatment of CA-VTE in patients with oral and facial cancer, such as swallowing difficulties, that might limit the possibilities of oral anticoagulation. Finally, there are limited data regarding the optimal treatment of CA-VTE in patients with oral and facial cancer, and this includes data on novel therapeutic strategies, including the use of direct oral anticoagulants. This article reviews current data on the optimal treatment strategy for CA-VTE in patients with OFC.https://www.mdpi.com/1424-8247/16/7/1011oral and facial cancercancer-associated venous thromboembolismdirect oral anticoagulantsparenteral anticoagulation |
| spellingShingle | Mária Janíčková Tomáš Bolek Lucia Stančiaková Norbert Nagy Marián Mokáň Matej Samoš How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism Pharmaceuticals oral and facial cancer cancer-associated venous thromboembolism direct oral anticoagulants parenteral anticoagulation |
| title | How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism |
| title_full | How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism |
| title_fullStr | How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism |
| title_full_unstemmed | How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism |
| title_short | How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism |
| title_sort | how to treat today oral and facial cancer associated venous thromboembolism |
| topic | oral and facial cancer cancer-associated venous thromboembolism direct oral anticoagulants parenteral anticoagulation |
| url | https://www.mdpi.com/1424-8247/16/7/1011 |
| work_keys_str_mv | AT mariajanickova howtotreattodayoralandfacialcancerassociatedvenousthromboembolism AT tomasbolek howtotreattodayoralandfacialcancerassociatedvenousthromboembolism AT luciastanciakova howtotreattodayoralandfacialcancerassociatedvenousthromboembolism AT norbertnagy howtotreattodayoralandfacialcancerassociatedvenousthromboembolism AT marianmokan howtotreattodayoralandfacialcancerassociatedvenousthromboembolism AT matejsamos howtotreattodayoralandfacialcancerassociatedvenousthromboembolism |